Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

被引：5
|
作者：
Chang, Sam S.
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 02期
关键词：
D O I：
10.1016/j.juro.2017.11.024
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：341 / 342
页数：2
相关论文
共 50 条
  • [31] Seasonal influences on the efficacy of anti-programmed cell death (ligand) 1 inhibitors in lung cancer
    Cho, Hyunsoon
    Kwon, Hoejun
    Kim, Se Hyun
    Ahn, Hyung-Min
    Choi, Beom K.
    Lee, Geon Kook
    Park, Seog-Yun
    Lim, Hyun-ju
    Hwang, Jung-Ah
    Lim, Jiyeon
    Han, Ji-Youn
    Lee, Youngjoo
    CANCER, 2024, 130 (21) : 3647 - 3657
  • [32] Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
    Haigentz, Missak
    Nemunaitis, John
    Johnson, Melissa
    Mohindra, Nisha
    Eaton, Keith
    Patel, Manish
    Awad, Mark
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Potvin, Diane
    Neskorik, Tavette
    Levisetti, Matteo
    Garon, Edward
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1073 - S1074
  • [33] Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer.
    Antonia, Scott Joseph
    Kim, Sang-We
    Spira, Alexander I.
    Ahn, Myung-Ju
    Ou, Sai-Hong Ignatius
    Stjepanovic, Neda
    Fasolo, Angela
    Jagert, Dirk
    Ottt, Patrick Alexander
    Wainberg, Zev A.
    Wakelee, Heather A.
    Goldman, Jonathan Wade
    Kurland, John
    Rebelatto, Marlon C.
    Yao, Wenliang
    Gupta, Ashok Kumar
    Blake-Haskins, John A.
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
    Segal, N. H.
    Ou, S-H. I.
    Balmanoukian, A. S.
    Massarelli, E.
    Brahmer, J. R.
    Weiss, J.
    Schoffski, P.
    Antonia, S. J.
    Massard, C.
    Zandberg, D. P.
    Maher, C.
    Khleif, S.
    Jin, X.
    Rebelatto, M.
    Steele, K.
    Antal, J.
    Gupta, A.
    Spreafico, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).
    Creelan, Ben C.
    Chow, Laura Q.
    Kim, Dong-Wan
    Kim, Sang-We
    Yeh, Tammie
    Karakunnel, Joyson Joseph
    Gibbons, Don Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
    Tang, Kimberly
    Seo, Jayhyun
    Tiu, Bruce C.
    Le, Thomas K.
    Pahalyants, Vartan
    Raval, Neel S.
    Ugwu-Dike, Pearl O.
    Zubiri, Leyre
    Naranbhai, Vivek
    Carrington, Mary
    Gusev, Alexander
    Reynolds, Kerry L.
    LeBoeuf, Nicole R.
    Asgari, Maryam M.
    Kwatra, Shawn G.
    Semenov, Yevgeniy R.
    JAMA DERMATOLOGY, 2022, 158 (02) : 189 - 193
  • [37] Efficacy of cross-line anti-programmed death 1/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study
    Zhao, Xiang
    Cheng, Yuan
    Guo, Cuiyan
    Nie, Ligong
    Zhang, Qi
    Zhang, Meng
    Sun, Kunyan
    Wang, Guangfa
    HEALTH SCIENCE REPORTS, 2024, 7 (05)
  • [38] Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC)
    Walker, J.
    Zajac, M.
    Ye, J.
    Scott, M.
    Ratcliffe, M.
    Scorer, P.
    Barker, C.
    Al-Masri, H.
    Rebelatto, M. C.
    Gupta, A.
    Mukhopadhay, P.
    Ferro, S.
    Powles, T.
    Williams, J. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 322 - 322
  • [39] Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma
    Zajac, Magdalena
    Boothman, Anne-Marie
    Ben, Yong
    Gupta, Ashok
    Jin, Xiaoping
    Mistry, Amita
    Sabalos, Constantine
    Nielsen, Alma
    Manriquez, Guadalupe
    Barker, Craig
    Antal, Joyce
    Wang, Peiyi
    Patil, Pallavi
    Schechter, Nicole
    Rebelatto, Marlon C.
    Walker, Jill
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2019, 143 (06) : 722 - 731
  • [40] A phase II study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Lee, Sylvia
    Villaflor, Viktoriya
    Haigentz, Missack
    Karyampudi, Kumar
    Tanamly, Susie
    Suzuki, Sam
    Gorbatchevsky, Igor
    Fardis, Maria
    Villaruz, Liza
    CANCER RESEARCH, 2018, 78 (13)
12345